Philip Morris International (PM) Gets FDA Backing For ZYN On Fair Value Stays In Focus

Simply Wall St.09:19

The U.S. Food and Drug Administration has granted Philip Morris International (PM) permission to market its ZYN nicotine pouches as modified risk tobacco products, marking the first such designation ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2654998440?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/6569181-main-header/1756256205773","is_english":true,"pubTime":"2026-07-27 09:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2654998440","market":"us","top_or_hot":-1,"title":"Philip Morris International (PM) Gets FDA Backing For ZYN On Fair Value Stays In Focus","media":"Simply Wall St.","content":"<div>\n<p>The U.S. Food and Drug Administration has granted Philip Morris International (PM) permission to market its ZYN nicotine pouches as modified risk tobacco products, marking the first such designation ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/food-beverage-tobacco/nyse-pm/philip-morris-international/news/philip-morris-international-pm-gets-fda-backing-for-zyn-on-f\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Philip Morris International (PM) Gets FDA Backing For ZYN On Fair Value Stays In Focus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPhilip Morris International (PM) Gets FDA Backing For ZYN On Fair Value Stays In Focus\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-27 09:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/food-beverage-tobacco/nyse-pm/philip-morris-international/news/philip-morris-international-pm-gets-fda-backing-for-zyn-on-f><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration has granted Philip Morris International (PM) permission to market its ZYN nicotine pouches as modified risk tobacco products, marking the first such designation ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/food-beverage-tobacco/nyse-pm/philip-morris-international/news/philip-morris-international-pm-gets-fda-backing-for-zyn-on-f\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GB00B4QBRK32.GBP","symbol_name":"FUNDSMITH EQUITY \"R\" (GBP) INC","start_time":0,"source_url":"https://simplywall.st/stocks/us/food-beverage-tobacco/nyse-pm/philip-morris-international/news/philip-morris-international-pm-gets-fda-backing-for-zyn-on-f","article_id":"2654998440","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/6569181-main-header/1756256205773"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/food-beverage-tobacco/nyse-pm/philip-morris-international/news/philip-morris-international-pm-gets-fda-backing-for-zyn-on-f","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2654998440","pubTimestamp":1785115163,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"The U.S. Food and Drug Administration has granted Philip Morris International (PM) permission to market its ZYN nicotine pouches as modified risk tobacco products, marking the first such designation for smoke free pouches in the U.S.\nSee our latest analysis for Philip Morris International.\nFor investors, this FDA milestone comes during a strong period for Philip Morris International, with a 19.95% 90 day share price return and a 143.58% five year total shareholder return. This suggests that...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"GB00B4QBRK32.GBP":"FUNDSMITH EQUITY \"R\" (GBP) INC","LU1228905037.USD":"NINETY ONE GSF GLOBAL QUALITY DIVIDEND GROWTH \"A\" (USD) ACC","LU2381873111.SGD":"BGF SYSTEMATIC GLOBAL EQUITY HIGH INCOME \"A6\" (SGDHDG) INC","LU1043141396.HKD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (HKD) ACC","GB00B4LPDJ14.GBP":"FUNDSMITH EQUITY \"R\" (GBP) ACC","LOHA":"Roundhill HALO ETF","LU1116320901.HKD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (HKD) INC","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","LU2404859741.USD":"FUNDSMITH EQUITY FUND \"R\" (USD) INC","FSTA":"Fidelity MSCI Consumer Staples Index ETF","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","LU1228905540.USD":"NINETY ONE GSF GLOBAL QUALITY DIVIDEND GROWTH \"A\" (USD) INC 2","LU1043141123.HKD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (HKD) INC 2","LU2404859667.USD":"FUNDSMITH EQUITY FUND \"R\" (USD) ACC","CGDG":"Capital Group Dividend Growers ETF","HK0000914686.HKD":"GFI Global Select Equity Fund Class A (HKD)","LU0314106906.USD":"MANULIFE GF GLOBAL EQUITY \"AA\" (USD) INC","LU0690374961.EUR":"FUNDSMITH EQUITY \"R\" (EUR) INC","BK4566":"资本集团","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","HK0000914660.USD":"GFI Global Select Equity Fund Class A (USD)","LU0690374615.EUR":"FUNDSMITH EQUITY \"R\" (EUR) ACC","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","ZYN":"Defiance Daily Target 2x Long PM ETF","LABU":"三倍做多标普生物-Direxion","LU0994945656.USD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (USD) INC 2","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","PM":"菲利普莫里斯","LU0545562505.USD":"NINETY ONE GSF GLOBAL QUALITY DIVIDEND GROWTH \"A\" (USD) INC","LU0949170772.SGD":"Blackrock Global Equity Income A6 SGD-H","BK4588":"碎股","LU1121112475.USD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (USDHDG) ACC","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","XLP":"消费品指数ETF-SPDR主要消费品","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","TRUO":"VanEck Consumer Staples TruSector ETF","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","UGE":"PROSHARES ULTRA CONSUMER STAPLES","NICO":"HEXIS ACTIVE NICOTINE ENGAGEMENT ETF","BK4075":"烟草","LU0426412945.USD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (USD) ACC","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","LU0426417589.USD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (USD) INC"},"translate_title":"菲利普莫里斯国际公司 (PM) 获得 FDA 对 ZYN 的支持，公允价值仍然是焦点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PM":1.5,"LABU":1.5,"XLP":0.6,"CGDG":0.6,"FSTA":0.6,"ZYN":1.5,"UGE":0.6,"NICO":0.6,"LOHA":1.5,"TRUO":0.6},"content_text":"The U.S. Food and Drug Administration has granted Philip Morris International (PM) permission to market its ZYN nicotine pouches as modified risk tobacco products, marking the first such designation for smoke free pouches in the U.S. See our latest analysis for Philip Morris International. For investors, this FDA milestone comes during a strong period for Philip Morris International, with a 19.95% 90 day share price return and a 143.58% five year total shareholder return. This suggests that recent momentum has been added to already robust long term gains. If the ZYN decision has you considering where regulation and growth intersect, this is a good moment to scan the market using our AI infrastructure and hardware enablers screener, starting with 55 AI infrastructure stocks Philip Morris International now trades only a few percent below both analyst price targets and an intrinsic value estimate, even after the ZYN driven jump. Is the market being cautious for good reason, or underpricing this new regulatory footing? AdvertisementMost Popular Narrative: 10% Undervalued At a last close of $193.00 versus a widely followed fair value of $193.14, the current price for Philip Morris International sits almost exactly on that narrative anchor, which is framed with a modest 10% undervaluation signal.  The accelerating global adoption of smoke-free alternatives, driven by increasing health awareness and regulatory moves away from combustibles, is associated with strong double-digit volume and margin growth in PMI's IQOS, ZYN, and VEEV platforms. This secular shift is described as enabling the company to capture new consumer segments, expand its addressable market, and structurally support higher net revenues and operating margins over time.  Read the complete narrative. Curious what sits behind that fair value for Philip Morris International? The narrative leans heavily on projected revenue expansion, rising margins and a future earnings multiple that assumes smoke free products keep pulling more weight. Result: Fair Value of $193.14 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the Philip Morris International narrative can still be challenged if cigarette volume declines outpace smoke free demand, or if future FDA and tax decisions become less supportive. Find out about the key risks to this Philip Morris International narrative. Another View on Philip Morris International’s Valuation The fair value narrative for Philip Morris International leans on future earnings power, but the current P/E of 27.7x stands well above both the global tobacco peer average of 11.5x and a fair ratio of 26x. That premium points to higher valuation risk if expectations soften, so how comfortable are you with paying up for this story? See what the numbers say about this price — find out in our valuation breakdown. NYSE:PM P/E Ratio as at Jul 2026Next Steps With Philip Morris International attracting mixed reactions around both risks and rewards, this is a moment to review the full picture quickly and decide where you stand using the 4 key rewards and 1 important warning sign Looking for more ideas beyond Philip Morris International? If this Philip Morris International update has sharpened your thinking, do not stop here. Broaden your watchlist with a few focused stock idea shortlists.  Target dependable income and stress test your current holdings against 9 dividend fortresses that may offer more resilient cash returns. Hunt for quality at a potentially attractive price by scanning our 49 high quality undervalued stocks that combine fundamentals with pricing that some investors may overlook. Prioritise capital preservation first and see which companies clear the bar in our 79 resilient stocks with low risk scores before you commit new money.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2654998440","isCrawlerRequest":true}